Izencitinib (TD-1473) is an orally active, nonselective, gut-defined JAK inhibitor. Izencitinib (TD-1473) can be used in ulcerative colitis studies.
| Molecular Weight | 402.5 |
| Formula | C22H26N8 |
| CAS Number | 2051918-33-1 |
| Solubility (25°C) | DMSO ≥ 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related JAK Products |
|---|
| SDC-1802
SDC-1802 is a JAK1/TYK2 inhibitor that can be used in studies related to systemic lupus erythematosus. |
| OST-246
OST-246 is an inhibitor of JAK3, MAP3K11, and TYK2 for studies related to autoimmune diseases and inflammation. |
| NDI-031232
NDI-031232 is a TYK2 inhibitor. |
| NDI-031301
NDI-031301 is a TYK2 inhibitor. |
| NDI-031407
NDI-031407 is a TYK2 inhibitor for studies related to endocrine metabolic diseases and psoriasis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
